Jim Gaffigan has a sleek new look to match his recent Hollywood renaissance, which includes his hilarious turn on SNL as vice ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Comedian Jim Gaffigan, whose new stand-up special, 'The Skinny', premieres on Nov. 22 on Hulu, has lost 50 lbs. with the help ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...

Data for tirzepatide, the chemical compound Lilly sells as Mounjaro and Zepbound, has separately showed the blockbuster ...